INM | InMed Pharmaceuticals Inc. | [NASD]
Index- P/E- EPS (ttm)-17.79 Insider Own0.15% Shs Outstand3.33M Perf Week-10.00%
Market Cap4.27M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.32M Perf Month5.00%
Income-15.50M PEG- EPS next Q- Inst Own12.30% Short Float / Ratio1.95% / 0.11 Perf Quarter-5.26%
Sales2.30M P/S1.86 EPS this Y12.60% Inst Trans27.53% Short Interest0.06M Perf Half Y-55.79%
Book/sh3.72 P/B0.34 EPS next Y- ROA-104.90% Target Price- Perf Year-93.70%
Cash/sh2.83 P/C0.44 EPS next 5Y- ROE-132.30% 52W Range0.92 - 20.00 Perf YTD-37.62%
Dividend- P/FCF- EPS past 5Y2.80% ROI-189.70% 52W High-93.70% Beta1.05
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin3.50% 52W Low36.76% ATR0.13
Employees13 Current Ratio5.20 Sales Q/Q233.30% Oper. Margin- RSI (14)50.15 Volatility8.13% 9.80%
OptionableNo Debt/Eq0.00 EPS Q/Q90.20% Profit Margin- Rel Volume0.11 Prev Close1.27
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume614.57K Price1.26
Recom3.00 SMA201.43% SMA501.15% SMA200-61.92% Volume64,768 Change-0.79%
May-24-23 06:51PM
May-18-23 05:00PM
May-15-23 12:33PM
Mar-28-23 07:30AM
Mar-13-23 07:30AM
08:35AM Loading…
Mar-10-23 08:35AM
Mar-07-23 08:35AM
Mar-06-23 06:00PM
Feb-17-23 05:00PM
Feb-09-23 09:41PM
Jan-10-23 07:30AM
Dec-15-22 06:17PM
Dec-12-22 06:47PM
Nov-23-22 12:18PM
05:00PM Loading…
Nov-21-22 05:00PM
Nov-18-22 08:00AM
Nov-17-22 10:32AM
Nov-16-22 12:13PM
Nov-11-22 06:51PM
Nov-10-22 07:30AM
Oct-26-22 07:30AM
Oct-24-22 10:13AM
Sep-23-22 12:29PM
Sep-19-22 06:00PM
Sep-13-22 05:12PM
Sep-09-22 05:00PM
Sep-08-22 02:08PM
05:00PM Loading…
Aug-23-22 05:00PM
Aug-09-22 07:30AM
Jul-25-22 07:30AM
Jul-18-22 07:30AM
Jul-12-22 11:33PM
Jun-14-22 07:30AM
Jun-09-22 07:30AM
Jun-06-22 06:49PM
Jun-02-22 08:00AM
May-13-22 08:45AM
May-05-22 07:30AM
May-03-22 12:00PM
Apr-28-22 07:30AM
Apr-21-22 07:30AM
Apr-19-22 07:30AM
Mar-17-22 07:30AM
Mar-08-22 07:30AM
Feb-16-22 07:30AM
Feb-15-22 07:30AM
Feb-14-22 08:45PM
Feb-10-22 07:30AM
Jan-19-22 07:30AM
Jan-05-22 07:30AM
Dec-30-21 07:30AM
Dec-20-21 07:30AM
Dec-17-21 07:57PM
Nov-23-21 07:30AM
Nov-18-21 12:23PM
Nov-17-21 08:25AM
Nov-10-21 09:05AM
Nov-03-21 07:30AM
Oct-22-21 12:48PM
Oct-18-21 07:02AM
Oct-15-21 11:14AM
Oct-13-21 04:30PM
Sep-30-21 08:46AM
Sep-24-21 12:31PM
Sep-20-21 07:50AM
Sep-17-21 01:14PM
Sep-13-21 11:47AM
Sep-09-21 07:18PM
Sep-07-21 04:04PM
Sep-03-21 08:35AM
Sep-02-21 08:35AM
Aug-25-21 01:27PM
Aug-12-21 12:00PM
Jul-02-21 04:15PM
Jun-29-21 07:00AM
Jun-28-21 08:35AM
Jun-22-21 12:29PM
Jun-21-21 08:35AM
Jun-17-21 07:30AM
Jun-15-21 06:41AM
Jun-09-21 11:30AM
May-13-21 09:15AM
May-06-21 07:30AM
May-04-21 07:30AM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.